Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Head and Neck Cancer
Interventions: Nivolumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions: Autologous Mesothelin-specific TCR-T Cells, Cyclophosphamide, Fludarabine, Bendamustine; Biological · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Non-Hodgkin Lymphoma, Myelodysplastic Syndromes
Interventions: Cord Blood Transplant; Procedure
Lead sponsor: Colorado Blood Cancer Institute; Other
Eligibility: 18 Years to 49 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Obesity
Interventions: Low calorie high fat/protein diet; Behavioral
Lead sponsor: Rockefeller University; Other
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer, Head and Neck Squamous Cell Cancer, Classical Hodgkin Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Urothelial Carcinoma, Microsatellite Instability-High Cancer, Gastric Cancer, Esophageal Cancer, Cervical Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Brain Metastases, Adult
Interventions: LITT + Pembrolizumab; Combination Product
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: Venetoclax, Decitabine, Fludarabine, Busulfan, Total Body Irradiation; Drug · Radiation
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Breast Cancer
Interventions: Celecoxib, Placebo, Cholecalciferol; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Grand Forks, North Dakota

Conditions: Prostate Cancer
Interventions: Enzalutamide, Leuprolide acetate, radiation; Drug · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Recurrent Glioma, High-grade Meningioma, Brain Metastasis
Interventions: Panobinostat, Stereotactic body radiation therapy, Quality-of-life assessment, Stereotactic radiosurgery; Drug · Radiation · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: PreDiabetes, Hyperglycemia, Glucose, High Blood, Overweight, Prediabetic State, Impaired Glucose Tolerance, Obesity, Weight Loss, Lifestyle, Healthy, Lifestyle Risk Reduction, Lifestyle, Sedentary
Interventions: Digital Diabetes Prevention Program (dDPP), Human Coach-based Diabetes Prevention Program (hDPP); Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Baltimore, Maryland • Reading, Pennsylvania

Conditions: Asthma
Interventions: fluticasone furoate, albuterol/salbutamol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 19
States / cities: Long Beach, California • Newport Beach, California • Colorado Springs, Colorado + 16 more

Conditions: GVHD - Graft-Versus-Host Disease
Interventions: Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III
Interventions: pNGVL4aCRTE6E7L2; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 19 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2029
U.S. locations: 2
States / cities: Birmingham, Alabama • Baltimore, Maryland

Conditions: COVID-19
Interventions: GAMUNEX-C, Standard Medical Treatment; Biological · Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 18
States / cities: Chandler, Arizona • Coronado, California • Chicago, Illinois + 15 more

Conditions: Diabetes Mellitus, Type 2
Interventions: CS-917, metformin hydrochloride, pioglitazone; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 66
States / cities: Birmingham, Alabama • Northport, Alabama • Mesa, Arizona + 62 more

Conditions: Albuminuria
Interventions: Ramipril + Irbesartan, Ramipril + Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 55 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 11
States / cities: Tustin, California • Miami, Florida • West Palm Beach, Florida + 8 more

Conditions: Non-Hodgkin's Lymphoma, CNS Lymphoma
Interventions: Autologous stem cell transplant, High-dose chemotherapy; Procedure · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Upper Tract Urothelial Carcinoma
Interventions: Signatera testing; Diagnostic Test
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Emesis
Interventions: Protein Shake; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 14 Years to 50 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Heart Failure
Interventions: hsTnT level; Other
Lead sponsor: Indiana University; Other
Eligibility: 21 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Indianapolis, Indiana • Detroit, Michigan • Cincinnati, Ohio + 1 more

Conditions: Healthy
Interventions: Physical Activity Level; Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 35 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2020
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Chronic Kidney Diseases, High Blood Pressure
Interventions: DASH diet counseling; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Advanced Triple Negative Breast Cancer (TNBC) With High TAMs
Interventions: MCS110, carboplatin, gemcitabine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Fayetteville, Arkansas • Boston, Massachusetts

Conditions: Mucopolysaccharidosis (MPS)
Interventions: Not listed
Lead sponsor: Shire; Industry
Eligibility: Up to 7 Years · Male only
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Los Angeles, California • Jacksonville, Florida • Minneapolis, Minnesota + 4 more

Search by objective public record fields.

Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions

Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation

High Fat - High Protein Diet in the Treatment of Obesity

LITT and Pembrolizumab in Recurrent Brain Metastasis

Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant

Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors

Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer

Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors

Effectiveness and Cost-Effectiveness of Fully-Automated Digital vs. Human Coach-Based Diabetes Prevention Programs

Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents

Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT

HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia

Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)

Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917

Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria

High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma

Circulating Tumor DNA (ctDNA) in High Grade Upper Tract Urothelial Cancer (UTUC)

High Protein Intake to Decrease Emesis and Promote Patient Satisfaction in Labor

High Sensitivity cTnT Rules Out Cardiac Insufficiency Trial (TACIT)

Mechanisms of the Effect of Physical Activity on the Adaptation to a High-Fat Diet

Diet and Hypertension Management in African Americans With Chronic Kidney Disease

Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)

Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric ENT Surgery (The HATT Project)